INVO Fertility, Inc (NASDAQ:IVF) Short Interest Up 21.1% in April

INVO Fertility, Inc (NASDAQ:IVF) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totaling 95,664 shares, a growth of 21.1% from the March 31st total of 79,020 shares. Based on an average trading volume of 45,391 shares, the days-to-cover ratio is presently 2.1 days. Currently, 6.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IVF. Maxim Group set a $20.00 price target on INVO Fertility in a report on Tuesday, February 10th. Wall Street Zen upgraded INVO Fertility from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.00.

INVO Fertility Stock Performance

Shares of IVF opened at $1.90 on Friday. The stock has a 50-day moving average of $3.18 and a two-hundred day moving average of $8.62. INVO Fertility has a one year low of $1.85 and a one year high of $360.00. The stock has a market cap of $3.08 million, a P/E ratio of 0.00 and a beta of 2.32.

Institutional Trading of INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Armistice Capital LLC purchased a new position in shares of INVO Fertility, Inc (NASDAQ:IVF) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 207,644 shares of the company’s stock, valued at approximately $156,000. Armistice Capital LLC owned 8.69% of INVO Fertility as of its most recent filing with the Securities and Exchange Commission. 12.02% of the stock is owned by hedge funds and other institutional investors.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.